Back

Factors influencing the up-titration to 10 mg target dose of vericiguat: data from a large observational cohort-study in the US.

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Congestion, SGLT2 inhibitors and novel therapies Pharmacotherapy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Alexander Michel

Bayer AG, Basel (Switzerland)

4 More presentations in this session

Presentation thumbnail
Optimisation of renin-angiotensin-aldosterone system inhibitors use in chronic kidney disease patients with heart failure: is hyperkalaemia a barrier?
Professor E. Kelepouris (Philadelphia, US)
Abstract Slides Video
Presentation thumbnail
Addition of sodium-glucose cotransporter-2 inhibitors on steroidal mineralocorticoid receptor antagonists eliminates hyperkalemia risk in diabetic heart failure patients with chronic kidney disease
Assistant Professor A. Sahin (Canakkale, TR)
Abstract Slides Video
Presentation thumbnail
Introduction and optimization of the guideline-directed medical therapy in patients hospitalized for acute heart failure (OPTICARD)
Doctor G. Baudry (Nancy, FR)
Abstract Slides Video
Presentation thumbnail
The impact on CD146 congestion biomarker by early adding SGLT2i dapaglifozin to intravenous loop diuretic in patients with acute heart failure
Doctor I. Lala (Timisoara, RO)
Abstract Slides Video

Access the full session

Session thumbnail
Congestion, SGLT2 inhibitors and novel therapies

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
Incidence of cardiovascular events following vericiguat initiation in patients with heart failure with or without a recent worsening heart failure event: a hospital-based real-world cohort study
thumbnail
Congress Presentation
Characteristics, patterns of co-medications and dose titration in heart failure patients using vericiguat in real-world clinical settings in Japan.
thumbnail
Congress Presentation
Clinical profile of heart failure patients starting vericiguat in clinical practice

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources